ABT vs ALB Stock Comparison

Scores Breakdown

Metric	ABT	ALB
📈 Growth	18/30	27/30
💰 Profitability	17/20	15/20
🏦 Financial Health	18/20	18/20
💵 Valuation	12/20	14/20
⚠️ Risk (lower is better)	4/10	7/10
Overall Score	71/100	77/100

Side-by-Side Summaries

ABT Analysis	ALB Analysis
📈 Growth & Financial Trajectory Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B. 💰 Margins & Cash Flow Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter. Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B). 🛡️ Balance Sheet & Liquidity Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow. ⚠️ Key Drivers & Risks Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management. Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.	📈 Growth & Financial Trajectory Across eight quarters, ALBEMARLE shows modest revenue growth from about $1.43B in 2024-Q2 to $1.74B in 2026-Q2, a gain of ~22%. Net income evolved from a loss of about -$176.6M to a positive $499.2M in 2026-Q2, with a mid-2025 dip, then a clear recovery into 2026. 💰 Margins & Cash Flow Gross margin expanded from a negative figure in 2024-Q2 to roughly 35% in 2025-Q1 and remained around the high 30% into 2026. Operating leverage benefited from higher margin production in later quarters. Net cash flow from operating activities, continuing, stayed strong, with $709.997M in 2026-Q2 and positive quarterly cash generation overall. Free cash flow was primarily consumed by investing activities, which were negative but the company still reported a positive overall cash flow in 2026-Q2. 🛡️ Balance Sheet & Liquidity Total assets of about $15.9B and equity of ~$10.5B support a solid balance sheet. Current assets of roughly $3.9B and current liabilities of $1.89B yield a healthy current ratio around 2.1x. Long-term debt remains moderate at about $1.88B, keeping balance-sheet risk contained. ⚠️ Key Drivers & Risks Drivers: Lithium/alloy battery demand; EV and energy-storage deployment Risks: commodity-price cyclicality; execution/valuation sensitivity to macro conditions

ABT Analysis

ALB Analysis

📈 Growth & Financial Trajectory

Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B.

💰 Margins & Cash Flow

Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter.
Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B).

🛡️ Balance Sheet & Liquidity

Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow.

⚠️ Key Drivers & Risks

Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management.
Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

📈 Growth & Financial Trajectory

Across eight quarters, ALBEMARLE shows modest revenue growth from about $1.43B in 2024-Q2 to $1.74B in 2026-Q2, a gain of ~22%. Net income evolved from a loss of about -$176.6M to a positive $499.2M in 2026-Q2, with a mid-2025 dip, then a clear recovery into 2026.

💰 Margins & Cash Flow

Gross margin expanded from a negative figure in 2024-Q2 to roughly 35% in 2025-Q1 and remained around the high 30% into 2026. Operating leverage benefited from higher margin production in later quarters. Net cash flow from operating activities, continuing, stayed strong, with $709.997M in 2026-Q2 and positive quarterly cash generation overall. Free cash flow was primarily consumed by investing activities, which were negative but the company still reported a positive overall cash flow in 2026-Q2.

🛡️ Balance Sheet & Liquidity

Total assets of about $15.9B and equity of ~$10.5B support a solid balance sheet. Current assets of roughly $3.9B and current liabilities of $1.89B yield a healthy current ratio around 2.1x. Long-term debt remains moderate at about $1.88B, keeping balance-sheet risk contained.

⚠️ Key Drivers & Risks

Drivers: Lithium/alloy battery demand; EV and energy-storage deployment
Risks: commodity-price cyclicality; execution/valuation sensitivity to macro conditions

Similar Companies

ABBV Score: 64 BSX Score: 79 DXCM Score: 82 ELV Score: 62 ISRG Score: 84 JNJ Score: 86 MDT Score: 78 TMO Score: 75 TSLA Score: 64

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"